Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Marzeptacog Alfa (Activated) in Treatment of Episodic Bleeding in Subjects With Inherited Bleeding Disorders

NCT04548791 is registered in ClinicalTrials.gov with Catalyst Biosciences as lead sponsor.

NCT NCT04548791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04548791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Marzeptacog Alfa (Activated) in Treatment of Episodic Bleeding in Subjects With Inherited Bleeding Disorders
Lead sponsor
Catalyst Biosciences
Phase
Phase 1/2
Overall status
Terminated
Start date
May 17, 2021
Completion date
December 3, 2021
Enrollment
19 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

factor vii deficiency, glanzmann thrombasthenia, hemophilia a with inhibitor